5/14
07:00 am
alks
Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
Low
Report
Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
5/14
07:00 am
alks
Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
Low
Report
Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
5/3
11:32 pm
alks
Alkermes plc (NASDAQ: ALKS) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
Alkermes plc (NASDAQ: ALKS) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
5/2
02:07 pm
alks
Alkermes plc (NASDAQ: ALKS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Low
Report
Alkermes plc (NASDAQ: ALKS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
5/2
01:42 pm
alks
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates [Yahoo! Finance]
Low
Report
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates [Yahoo! Finance]
5/2
07:00 am
alks
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
Low
Report
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
5/2
07:00 am
alks
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
Low
Report
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
5/1
11:25 am
alks
Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
Low
Report
Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
5/1
07:12 am
alks
Alkermes plc Reports First Quarter 2024 Financial Results [Yahoo! Finance]
Low
Report
Alkermes plc Reports First Quarter 2024 Financial Results [Yahoo! Finance]
5/1
07:00 am
alks
Alkermes plc Reports First Quarter 2024 Financial Results
Low
Report
Alkermes plc Reports First Quarter 2024 Financial Results
5/1
07:00 am
alks
Alkermes plc Reports First Quarter 2024 Financial Results
Low
Report
Alkermes plc Reports First Quarter 2024 Financial Results
4/24
07:10 am
alks
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 [Yahoo! Finance]
Low
Report
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 [Yahoo! Finance]
4/24
07:00 am
alks
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
Low
Report
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
4/24
07:00 am
alks
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
Low
Report
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
4/22
03:58 pm
alks
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition? [Yahoo! Finance]
Neutral
Report
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition? [Yahoo! Finance]
4/19
08:03 am
alks
Alkermes plc (NASDAQ: ALKS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Low
Report
Alkermes plc (NASDAQ: ALKS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
4/17
04:00 pm
alks
Alkermes to Report First Quarter Financial Results on May 1, 2024
Low
Report
Alkermes to Report First Quarter Financial Results on May 1, 2024
4/17
04:00 pm
alks
Alkermes to Report First Quarter Financial Results on May 1, 2024
Low
Report
Alkermes to Report First Quarter Financial Results on May 1, 2024
4/16
11:29 am
alks
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
Low
Report
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
4/11
11:41 am
alks
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study [Yahoo! Finance]
Low
Report
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study [Yahoo! Finance]
4/9
12:09 pm
alks
Alkermes plc (NASDAQ: ALKS) had its price target raised by analysts at Jefferies Financial Group Inc. from $42.00 to $50.00. They now have a "buy" rating on the stock.
Low
Report
Alkermes plc (NASDAQ: ALKS) had its price target raised by analysts at Jefferies Financial Group Inc. from $42.00 to $50.00. They now have a "buy" rating on the stock.
4/9
09:53 am
alks
Alkermes Plc: Collecting The Fruits Of The 2023 Spinoff [Seeking Alpha]
Low
Report
Alkermes Plc: Collecting The Fruits Of The 2023 Spinoff [Seeking Alpha]
4/9
07:15 am
alks
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia [Yahoo! Finance]
Low
Report
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia [Yahoo! Finance]
4/9
07:00 am
alks
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
Medium
Report
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
4/9
07:00 am
alks
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
Medium
Report
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia